Arginine methylation is a prevalent post-translational modification found on both nuclear and cytoplasmic proteins. The methylation of arginine residues is catalyzed by the protein arginine N-methyltransferase (PRMT) family of enzymes. Proteins that are arginine methylated are involved in a number of different cellular processes, including transcriptional regulation, RNA metabolism and DNA damage repair (Bedford and Richard, 2005). Most PRMTs methylate glycine- and arginine-rich patches (GAR motifs) within their substrates. The complexity of the methylarginine mark is enhanced by the ability of this residue to be methylated in three different ways on the guanidino group: monomethylated (MMA), symmetrically dimethylated (sDMA) and asymmetrically dimethylated (aDMA), each of which has potentially different functional consequences.

There are three structurally defined types of S-adenosylmethionine (AdoMet)-dependent methyltransferase (Katz et al., 2003). The largest class (Class I) has a common seven-stranded β-sheet structure. The Class II enzymes are the SET lysine methyltransferases and Class III encompasses the membrane-associated methyltransferases. PRMT family members fall into Class I and harbor a set of four conserved sequence motifs (I, post-I, II, and III) and a THW loop (Katz et al., 2003). Motifs I, post-I and the THW loop form part of the AdoMet-binding pocket (Zhang et al., 2000). Ten mammalian PRMTs have been identified to date. Eight have been shown to catalyze the transfer of a methyl group from AdoMet to a guanidino nitrogen of arginine, generating S-adenosylhomocysteine (AdoHcy) and methylarginine. No activity has yet been demonstrated for PRMT2 and PRMT9.

PRMTs are classified as type I, type II, type III or type IV enzymes. Types I, II and III enzymes methylate the terminal (or ω) guanidino nitrogen atoms. Type I and type II enzymes all catalyze the formation of an MMA intermediate, then type I PRMTs (PRMT1, 3, 4, 6 and 8) further catalyze the production of aDMA, whereas type II PRMTs (PRMT5, PRMT7 and FBXO11) catalyze the formation of sDMA. PRMT7 also exhibits type III enzymatic activity – the propensity to catalyze the formation of MMA on certain substrates and not proceed with sDMA catalysis. A type IV enzyme that catalyzes the monomethylation of the internal (or δ) guanidino nitrogen atom has been described in yeast.

PRMT1

PRMT1, the predominant mammalian type I enzyme, was identified by sequence similarity to the yeast arginine methyltransferase Hmt1/Rmt1 (Lin et al., 1996). PRMT1 is broadly expressed and localizes to both the cytoplasm and the nucleus and has substrates in both these cellular compartments (Herrmann et al., 2005). PRMT1 methylates a number of hnRNP molecules, and this modification plays a role in the shuttling of these proteins between the cytoplasm and the nucleus (Herrmann et al., 2004). PRMT1 also methylates histone H4 at arginine 3 (Wang et al., 2001), thus contributing to the histone code. This modification on histone H4 functions as a transcriptional activation mark, which could either result in the recruitment of methyl-binding proteins or influence the deposition of other posttranslational marks in the vicinity. As a transcriptional coactivator, PRMT1 is recruited to promoters by a number of different transcription factors (Bedford and Richard, 2005). The central role that PRMT1 plays as a regulator of protein function is revealed by the disruption of this enzyme in mice. PRMT1-knockout mice die shortly after implantation (Pawlak et al., 2000). The crystal structure of PRMT1 in complex with the reaction product (AdoHcy) and a GAR motif has been described (Zhang and Cheng, 2003).

PRMT2

The first relative of PRMT1 to be identified was PRMT2 (Katsanis et al., 1997). A novel feature of PRMT2 is that it harbors an SH3 domain at its N-terminus (Scott et al., 1998). Although PRMT2 does not have enzymatic activity, it does function as a coactivator for the estrogen receptor (Qi et al., 2002). PRMT2-null mice are viable and grossly normal (Yoshimoto et al., 2006).

PRMT3

A unique property of PRMT3 is that it harbors a zinc-finger domain at its N-terminus, which is its substrate-recognition module (Tang et al., 1998). The 40S ribosomal protein S2 (rpS2) is a zinc-finger-dependent substrate of mammalian PRMT3 (Swiercz et al., 2005). Importantly, in fission yeast this same enzyme-substrate pair (PRMT3-rpS2) exists (Bachand and Silver, 2004), and the disruption of the prmt3 gene in this organism results in an imbalance in the 40S:60S free subunit ratio. Mouse embryos with a targeted disruption of PRMT3 are small, but survive after birth and attain a normal size in adulthood. The ribosome protein rpS2 is hypomethylated in the absence of PRMT3, which demonstrates that it is an in vivo PRMT3 substrate (Swiercz et al., 2007).

CARM1

CARM1, sometimes referred to as PRMT4, was identified in a yeast two-hybrid for proteins that associate with GRIP1, the p160 steroid receptor coactivator (Chen et al., 1999). The recruitment of CARM1 to promoters results in the methylation of histone H3 at Arg17 and of other coactivators including p300/CBP and AIB1 (Bedford and Richard, 2005). CARM1-mediated methylation has a positive effect on transcription. CARM1 is not only a steroid receptor coactivator but also enhances transcription/translation rates in pathways responding to other transcription factors (Bedford and Richard, 2005). In addition, CARM1 methylates splicing factors and regulates the coupling of transcription and splicing (Cheng et al., 2007). CARM1-null mice die just after birth and are smaller than their wild-type littermates (Yadav et al., 2003). Cells from CARM1-null embryos have defective estrogen receptor and NF-κB pathways. CARM1 has also been implicated in the epigenetic programming of early embryos (Torres-Padilla et al., 2007). Finally, the fact that CARM1 is a coactivator for nuclear receptors makes it a likely candidate for over-expression in prostate and breast cancers. Indeed, increased expression of CARM1 correlates with androgen independence in human prostate carcinoma (Hong et al., 2004) and CARM1 is overexpressed in breast tumors (El Messaoudi et al., 2006).

PRMT5

PRMT5 was cloned as Jak2-binding protein and shown to methylate histones H2A, H3 and H4 (Branscombe et al., 2001; Pollack et al., 1999). It localizes to both the cytoplasm and the nucleus. In the cytoplasm, PRMT5 is found in the `methylosome', where it is involved in the methylation of Sm proteins, which implicates it in snRNP biogenesis (Friesen et al., 2001). Nuclear PRMT5 associates with regulators of transcriptional elongation SPT4 and SPT5 (Kwak et al., 2003). Nuclear PRMT5 also forms complexes with the hSWI/SNF chromatin-remodeling proteins BRG and BRM, where it is responsible for methylating Arg8 on histone H3 (Pal et al., 2004) and is required for muscle differentiation (Dacwag et al., 2007). PRMT5 and H3R8 methylation levels are elevated in lymphoid cancer cells (Pal et al., 2007). A general note of caution should be added here: the Reinberg group have found that αFLAG M2-agarose enriches for PRMT5 activity (Nishioka and Reinberg, 2003); thus many affinity-purified FLAG-tagged complexes are `contaminated' with PRMT5.

PRMT6

PRMT6 is restricted to the nucleus and it has the ability to methylate itself (Frankel et al., 2002). Like PRMT1, PRMT6 methylates a GAR motif. However, it displays unique substrate specificity – it methylates histones H3 and H4 in vitro, whereas PRMT1 only methylates histone H4 (Lee et al., 2004). DNA polymerase β was found to form a complex with PRMT6. Methylation of Pol β by PRMT6 strongly stimulates DNA polymerase activity (El-Andaloussi et al., 2006). Thus, PRMT6 plays a role regulating DNA base excision repair. Finally, PRMT6 has also been shown to methylate a number of HIV proteins (Invernizzi et al., 2007).

PRMT7

PRMT7 was first identified in a genetic screen for susceptibility to chemotherapeutic cytotoxicity (Gros et al., 2003). It is one of two PRMTs that harbor two putative AdoMet-binding motifs (Miranda et al., 2004). It has a strong propensity to catalyze the formation of MMA but not DMA on a fibrillarin-derived peptide substrate (Miranda et al., 2004). Miranda et al. thus classified PRMT7 as a type III enzyme. Using a different peptide substrate, Lee et al. showed that PRMT7 catalyzes the formation of sDMA, consequently classifying it as a type II enzyme (Lee et al., 2005b). It is possible that distinct substrates are methylated in different fashions by this enzyme. A study that focused on identifying loci that impart susceptibility to drug-induced nephropathy has implicated PRMT7 as a candidate (Zheng et al., 2005). Also, PRMT7 plays a role in male germline imprinted gene methylation through its interaction with CTCFL (a protein that associates with the imprinting control region) and subsequent methylation of histone 4 Arg3 (Jelinic et al., 2006).

PRMT8

PRMT8 was identified through its high degree of sequence identity to PRMT1 (Lee et al., 2005a). PRMT8 has a unique N-terminus that harbors a myristoylation motif that facilitates its association with the plasma membrane. It is largely restricted to the brain.

PRMT9 (4q31)

PRMT9 (4q31) was first identified at the same time that PRMT8 was described (Lee et al., 2005a). In common with PRMT7, it harbors two putative AdoMet-binding motifs. In addition, at its N-terminus PRMT9 has a TPR repeat, which may be a protein-protein interaction module (Bedford, 2006).

FBXO11

FBXO11, also referred to as PRMT9 (2p16.3), was identified as a potential PRMT because it has regions that display weak sequence similarity to the I, post-I, II and III amino acid sequence motifs (Cook et al., 2006). Unlike other PRMTs, it does not harbor a THW loop; however, FLAG-tagged hFBXO11 has been reported to have type II activity (Cook et al., 2006), but HA-tagged hFBXO11 and its C. elegans ortholog (DRE-1) have been reported not to have PRMT activity (Fielenbach et al., 2007).

Proteins that harbor GAR motifs are often targets for PRMTs, although CARM1 is an exception and cannot methylate a GAR motif. Recent advances in mass spectrometry mean that more and more isolated methylation sites that are not within GAR motifs are being identified. In addition, both CARM1 and PRMT5 can also methylate PGM motifs (Cheng et al., 2007). PGM motifs are proline-, glycine-, methionine-, arginine-rich patches that are found in a number of splicing factors (Bedford et al., 1998). PRMT substrates have been extensively reviewed recently (McBride, 2006; Pahlich et al., 2006).

Arginine methylation facilitates the interaction of GAR and PGM motifs with Tudor domains. The symmetric dimethylation of SmB by PRMT5 is required for its interaction with the Tudor domains of SMN, SPF30 and TDRD3 (Cote and Richard, 2005). The asymmetric dimethylation of CA150 by CARM1 also provides a docking site for the Tudor domain of SMN (Cheng et al., 2007). Thus, motifs harboring either aDMA or sDMA residues bind a subset of Tudor-domain-containing proteins. It is likely that a conserved aromatic `cage' in Tudor domains is the methyl-binding pocket (Sprangers et al., 2003).

Arginine methylation can also act as a negative regulator of protein-protein interactions. For example, the methylation of arginine residues adjacent to a proline-rich motif can block binding to SH3, but not WW, domains (Bedford et al., 2000). A second example is the CARM1-mediated modification of the GRIP1-binding domain of p300 (Lee et al., 2005c). Finally, histone H3 methylation at Lys4 provides a docking site for the double chromodomains of CHD1 (chromo-helicase/ATPase DNA-binding protein 1). The histone H3 Arg2 site is reported to be methylated by CARM1, and this methylation together with Lys4 methylation (H3K4me3R2me2a) decreases the binding affinity fourfold relative to histone H3 Lys4 methylation alone (Flanagan et al., 2005).

PRMT-binding proteins can regulate the activity of PRMTs. They can inhibit, activate, or change the substrate specificity of PRMTs. The related proteins BTG1 and TIS2/BTG2 bind to PRMT1 and stimulate its activity towards selected substrates (Lin et al., 1996). The BTG1-binding protein hCAF1 also regulates PRMT1 activity (Robin-Lespinasse et al., 2007). Binding of the tumor suppressor DAL-1 to PRMT3 acts as an inhibitor of enzyme activity, both in vitro and in cell lines (Singh et al., 2004). CARM1 is found in a complex of at least 10 proteins called the nucleosomal methylation activator complex (NUMAC) (Xu et al., 2004). CARM1 within NUMAC acquires the ability to methylate nucleosomal histone H3, whereas recombinant CARM1 preferentially methylates free histone H3. PRMT5 forms complexes with the hSWI/SNF chromatin remodelers BRG and BRM, and this association enhances PRMT5 methyltransferase activity (Pal et al., 2004). The binding of CTCFL to PRMT7 has also been reported to elevate the activity of this PRMT (Jelinic et al., 2006).

Arginine residues within proteins can be converted to citrulline by deimination. A major group of deiminated proteins are the core histones H2A, H3 and H4 (Nakashima et al., 2002). The peptidyl arginine deiminases (PADs) can block methylation on an arginine residue by converting it to citrulline (Cuthbert et al., 2004; Wang et al., 2004). PADs catalyze the deimination of arginine, but not MMA or DMA, to citrulline (Raijmakers et al., 2007). Thus, peptidyl arginine deiminases are not demethylases. However, these enzymes may carry out a preemptive strike on key sites of arginine methylation, thereby preventing subsequent methylation. The first evidence that PRMTs themselves are regulated by posttranslational events was recently described (Higashimoto et al., 2007). In this case, the phosphorylation of CARM1 results in a decrease in PRMT activity. There are no reported arginine demethylases and this topic is an active area of research.

The first arginine demethylase has been identified very recently (Chang et al., 2007). This protein, JMJD6, is a Jumonji-domain-containing protein. In addition, PRMT6 has recently been shown to methylate H3R2 (Guccione et al., 2007).

Thank you to Steven Clarke for his comments on this review. M.T.B. is supported by NIH grant DK62248.

Bachand, F. and Silver, P. A. (
2004
). PRMT3 is a ribosomal protein methyltransferase that affects the cellular levels of ribosomal subunits.
EMBO J.
23
,
2641
-2650.
Bedford, M. T. (
2006
). The family of protein arginine methyltransferases. In
The Enzymes
(ed. S. G. Clarke and F. Tamanoi), pp.
31
-50. Amsterdam: Academic Press.
Bedford, M. T. and Richard, S. (
2005
). Arginine methylation an emerging regulator of protein function.
Mol. Cell
18
,
263
-272.
Bedford, M. T., Reed, R. and Leder, P. (
1998
). WW domain-mediated interactions reveal a spliceosome-associated protein that binds a third class of proline-rich motif: the proline glycine and methionine-rich motif.
Proc. Natl. Acad. Sci. USA
95
,
10602
-10607.
Bedford, M. T., Frankel, A., Yaffe, M. B., Clarke, S., Leder, P. and Richard, S. (
2000
). Arginine methylation inhibits the binding of proline-rich ligands to Src homology 3, but not WW, domains.
J. Biol. Chem.
275
,
16030
-16036.
Branscombe, T. L., Frankel, A., Lee, J. H., Cook, J. R., Yang, Z., Pestka, S. and Clarke, S. (
2001
). Prmt5 (janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins.
J. Biol. Chem.
276
,
32971
-32976.
Chang, B., Chen, Y., Zhao, Y. and Bruick, R. K. (
2007
). JMJD6 is a histone arginine demethylase.
Science
318
,
444
-447.
Chen, D., Ma, H., Hong, H., Koh, S. S., Huang, S. M., Schurter, B. T., Aswad, D. W. and Stallcup, M. R. (
1999
). Regulation of transcription by a protein methyltransferase.
Science
284
,
2174
-2177.
Cheng, D., Cote, J., Shaaban, S. and Bedford, M. T. (
2007
). The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing.
Mol. Cell
25
,
71
-83.
Cook, J. R., Lee, J. H., Yang, Z. H., Krause, C. D., Herth, N., Hoffmann, R. and Pestka, S. (
2006
). FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues.
Biochem. Biophys. Res. Commun.
342
,
472
-481.
Cote, J. and Richard, S. (
2005
). Tudor domains bind symmetrical dimethylated arginines.
J. Biol. Chem.
280
,
28476
-28483.
Cuthbert, G. L., Daujat, S., Snowden, A. W., Erdjument-Bromage, H., Hagiwara, T., Yamada, M., Schneider, R., Gregory, P. D., Tempst, P., Bannister, A. J. et al. (
2004
). Histone deimination antagonizes arginine methylation.
Cell
118
,
545
-553.
Dacwag, C. S., Ohkawa, Y., Pal, S., Sif, S. and Imbalzano, A. N. (
2007
). The protein arginine methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-dependent chromatin remodeling.
Mol. Cell. Biol.
27
,
384
-394.
El-Andaloussi, N., Valovka, T., Toueille, M., Steinacher, R., Focke, F., Gehrig, P., Covic, M., Hassa, P. O., Schar, P., Hubscher, U. et al. (
2006
). Arginine methylation regulates DNA polymerase Beta.
Mol. Cell
22
,
51
-62.
El Messaoudi, S., Fabbrizio, E., Rodriguez, C., Chuchana, P., Fauquier, L., Cheng, D., Theillet, C., Vandel, L., Bedford, M. T. and Sardet, C. (
2006
). Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene.
Proc. Natl. Acad. Sci. USA
103
,
13351
-13356.
Fielenbach, N., Guardavaccaro, D., Neubert, K., Chan, T., Li, D., Feng, Q., Hutter, H., Pagano, M. and Antebi, A. (
2007
). DRE-1: an evolutionarily conserved F box protein that regulates C. elegans developmental age.
Dev. Cell
12
,
443
-455.
Flanagan, J. F., Mi, L. Z., Chruszcz, M., Cymborowski, M., Clines, K. L., Kim, Y., Minor, W., Rastinejad, F. and Khorasanizadeh, S. (
2005
). Double chromodomains cooperate to recognize the methylated histone H3 tail.
Nature
438
,
1181
-1185.
Frankel, A., Yadav, N., Lee, J., Branscombe, T. L., Clarke, S. and Bedford, M. T. (
2002
). The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity.
J. Biol. Chem.
277
,
3537
-3543.
Friesen, W. J., Paushkin, S., Wyce, A., Massenet, S., Pesiridis, G. S., Van Duyne, G., Rappsilber, J., Mann, M. and Dreyfuss, G. (
2001
). The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins.
Mol. Cell. Biol.
21
,
8289
-8300.
Guccione, E., Bassi, C., Casadio, F., Martinato, F., Cesaroni, M., Schuchlautz, H., Lüscher, B. and Amati B. (
2007
). Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive.
Nature
449
,
933
-937.
Gros, L., Delaporte, C., Frey, S., Decesse, J., de Saint-Vincent, B. R., Cavarec, L., Dubart, A., Gudkov, A. V. and Jacquemin-Sablon, A. (
2003
). Identification of new drug sensitivity genes using genetic suppressor elements: protein arginine N-methyltransferase mediates cell sensitivity to DNA-damaging agents.
Cancer Res.
63
,
164
-171.
Herrmann, F., Bossert, M., Schwander, A., Akgun, E. and Fackelmayer, F. O. (
2004
). Arginine methylation of scaffold attachment factor A by heterogeneous nuclear ribonucleoprotein particle-associated PRMT1.
J. Biol. Chem.
279
,
48774
-48779.
Herrmann, F., Lee, J., Bedford, M. T. and Fackelmayer, F. O. (
2005
). Dynamics of human protein arginine methyltransferase 1 (PRMT1) in vivo.
J. Biol. Chem.
280
,
38005
-38010.
Higashimoto, K., Kuhn, P., Desai, D., Cheng, X. and Xu, W. (
2007
). Phosphorylation-mediated inactivation of coactivator-associated arginine methyltransferase 1.
Proc. Natl. Acad. Sci. USA
104
,
12318
-12323.
Hong, H., Kao, C., Jeng, M. H., Eble, J. N., Koch, M. O., Gardner, T. A., Zhang, S., Li, L., Pan, C. X., Hu, Z. et al. (
2004
). Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.
Cancer
101
,
83
-89.
Invernizzi, C. F., Xie, B., Frankel, F. A., Feldhammer, M., Roy, B. B., Richard, S. and Wainberg, M. A. (
2007
). Arginine methylation of the HIV-1 nucleocapsid protein results in its diminished function.
Aids
21
,
795
-805.
Jelinic, P., Stehle, J. C. and Shaw, P. (
2006
). The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation.
PLoS Biol.
4
,
e355
.
Katsanis, N., Yaspo, M. L. and Fisher, E. M. (
1997
). Identification and mapping of a novel human gene, HRMT1L1, homologous to the rat protein arginine N-methyltransferase 1 (PRMT1) gene.
Mamm. Genome
8
,
526
-529.
Katz, J. E., Dlakic, M. and Clarke, S. (
2003
). Automated identification of putative methyltransferases from genomic open reading frames.
Mol. Cell. Proteomics
2
,
525
-540.
Kwak, Y. T., Guo, J., Prajapati, S., Park, K. J., Surabhi, R. M., Miller, B., Gehrig, P. and Gaynor, R. B. (
2003
). Methylation of SPT5 regulates its interaction with RNA polymerase II and transcriptional elongation properties.
Mol. Cell
11
,
1055
-1066.
Lee, J., Cheng, D. and Bedford, M. T. (
2004
). Techniques in protein methylation.
Methods Mol. Biol.
284
,
195
-208.
Lee, J., Sayegh, J., Daniel, J., Clarke, S. and Bedford, M. T. (
2005a
). PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family.
J. Biol. Chem.
280
,
32890
-32896.
Lee, J. H., Cook, J. R., Yang, Z. H., Mirochnitchenko, O., Gunderson, S. I., Felix, A. M., Herth, N., Hoffmann, R. and Pestka, S. (
2005b
). PRMT7, a new protein arginine methyltransferase that synthesizes symmetric dimethylarginine.
J. Biol. Chem.
280
,
3656
-3664.
Lee, Y. H., Coonrod, S. A., Kraus, W. L., Jelinek, M. A. and Stallcup, M. R. (
2005c
). Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination.
Proc. Natl. Acad. Sci. USA
102
,
3611
-3616.
Lin, W. J., Gary, J. D., Yang, M. C., Clarke, S. and Herschman, H. R. (
1996
). The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase.
J. Biol. Chem.
271
,
15034
-15044.
McBride, A. E. (
2006
). Diverse roles of protein arginine methylation. In
The Enzymes
(ed. S. G. Clarke and F. Tamanoi), pp.
51
-104. Amsterdam: Academic Press.
Miranda, T. B., Miranda, M., Frankel, A. and Clarke, S. (
2004
). PRMT7 is a member of the protein arginine methyltransferase family with a distinct substrate specificity.
J. Biol. Chem.
279
,
22902
-22907.
Nakashima, K., Hagiwara, T. and Yamada, M. (
2002
). Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes.
J. Biol. Chem.
277
,
49562
-49568.
Nishioka, K. and Reinberg, D. (
2003
). Methods and tips for the purification of human histone methyltransferases.
Methods
31
,
49
-58.
Pahlich, S., Zakaryan, R. P. and Gehring, H. (
2006
). Protein arginine methylation: cellular functions and methods of analysis.
Biochim. Biophys. Acta
1764
,
1890
-1903.
Pal, S., Vishwanath, S. N., Erdjument-Bromage, H., Tempst, P. and Sif, S. (
2004
). Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes.
Mol. Cell. Biol.
24
,
9630
-9645.
Pal, S., Baiocchi, R. A., Byrd, J. C., Grever, M. R., Jacob, S. T. and Sif, S. (
2007
). Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
EMBO J.
26
,
3558
-3569.
Pawlak, M. R., Scherer, C. A., Chen, J., Roshon, M. J. and Ruley, H. E. (
2000
). Arginine N-methyltransferase 1 is required for early postimplantation mouse development, but cells deficient in the enzyme are viable.
Mol. Cell. Biol.
20
,
4859
-4869.
Pollack, B. P., Kotenko, S. V., He, W., Izotova, L. S., Barnoski, B. L. and Pestka, S. (
1999
). The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity.
J. Biol. Chem.
274
,
31531
-31542.
Qi, C., Chang, J., Zhu, Y., Yeldandi, A. V., Rao, S. M. and Zhu, Y. J. (
2002
). Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha.
J. Biol. Chem.
277
,
28624
-28630.
Raijmakers, R., Zendman, A. J., Egberts, W. V., Vossenaar, E. R., Raats, J., Soede-Huijbregts, C., Rutjes, F. P., van Veelen, P. A., Drijfhout, J. W. and Pruijn, G. J. (
2007
). Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro.
J. Mol. Biol.
367
,
1118
-1129.
Robin-Lespinasse, Y., Sentis, S., Kolytcheff, C., Rostan, M. C., Corbo, L. and Le Romancer, M. (
2007
). hCAF1, a new regulator of PRMT1-dependent arginine methylation.
J. Cell Sci.
120
,
638
-647.
Scott, H. S., Antonarakis, S. E., Lalioti, M. D., Rossier, C., Silver, P. A. and Henry, M. F. (
1998
). Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2).
Genomics
48
,
330
-340.
Singh, V., Miranda, T. B., Jiang, W., Frankel, A., Roemer, M. E., Robb, V. A., Gutmann, D. H., Herschman, H. R., Clarke, S. and Newsham, I. F. (
2004
). DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo.
Oncogene
23
,
7761
-7771.
Sprangers, R., Groves, M. R., Sinning, I. and Sattler, M. (
2003
). High-resolution X-ray and NMR structures of the SMN Tudor domain: conformational variation in the binding site for symmetrically dimethylated arginine residues.
J. Mol. Biol.
327
,
507
-520.
Swiercz, R., Person, M. D. and Bedford, M. T. (
2005
). Ribosomal protein S2 is a substrate for mammalian PRMT3 (protein arginine methyltransferase 3).
Biochem. J.
386
,
85
-91.
Swiercz, R., Cheng, D., Kim, D. and Bedford, M. T. (
2007
). Ribosomal protein rpS2 is hypomethylated in PRMT3-deficient mice.
J. Biol. Chem.
282
,
16917
-16923.
Tang, J., Gary, J. D., Clarke, S. and Herschman, H. R. (
1998
). PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation.
J. Biol. Chem.
273
,
16935
-16945.
Torres-Padilla, M. E., Parfitt, D. E., Kouzarides, T. and Zernicka-Goetz, M. (
2007
). Histone arginine methylation regulates pluripotency in the early mouse embryo.
Nature
445
,
214
-218.
Wang, H., Huang, Z. Q., Xia, L., Feng, Q., Erdjument-Bromage, H., Strahl, B. D., Briggs, S. D., Allis, C. D., Wong, J., Tempst, P. et al. (
2001
). Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor.
Science
293
,
853
-857.
Wang, Y., Wysocka, J., Sayegh, J., Lee, Y. H., Perlin, J. R., Leonelli, L., Sonbuchner, L. S., McDonald, C. H., Cook, R. G., Dou, Y. et al. (
2004
). Human PAD4 regulates histone arginine methylation levels via demethylimination.
Science
306
,
279
-283.
Xu, W., Cho, H., Kadam, S., Banayo, E. M., Anderson, S., Yates, J. R., 3rd, Emerson, B. M. and Evans, R. M. (
2004
). A methylation-mediator complex in hormone signaling.
Genes Dev.
18
,
144
-156.
Yadav, N., Lee, J., Kim, J., Shen, J., Hu, M. C., Aldaz, C. M. and Bedford, M. T. (
2003
). Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice.
Proc. Natl. Acad. Sci. USA
100
,
6464
-6468.
Yoshimoto, T., Boehm, M., Olive, M., Crook, M. F., San, H., Langenickel, T. and Nabel, E. G. (
2006
). The arginine methyltransferase PRMT2 binds RB and regulates E2F function.
Exp. Cell Res.
312
,
2040
-2053.
Zhang, X. and Cheng, X. (
2003
). Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides.
Structure
11
,
509
-520.
Zhang, X., Zhou, L. and Cheng, X. (
2000
). Crystal structure of the conserved core of protein arginine methyltransferase PRMT3.
EMBO J.
19
,
3509
-3519.
Zheng, Z., Schmidt-Ott, K. M., Chua, S., Foster, K. A., Frankel, R. Z., Pavlidis, P., Barasch, J., D'Agati, V. D. and Gharavi, A. G. (
2005
). A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse.
Proc. Natl. Acad. Sci. USA
102
,
2502
-2507.